Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
06 05 2022
06 05 2022
Historique:
received:
05
10
2021
accepted:
25
04
2022
revised:
21
04
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
According to the EPOC study, chemotherapy could improve 5-year disease-free survival of stage IV colon cancer patients by 8.1%. However, more molecular biomarkers are required to identify patients who need neoadjuvant chemotherapy. DENND2D expression was evaluated by immunohistochemistry in 181 stage IV colon cancer patients. The prognosis was better for patients with DENND2D expression than patients without DENND2D expression (5-year overall survival [OS]: 42% vs. 12%, p = 0.038; 5-year disease-free survival: 20% vs. 10%, p = 0.001). Subgroup analysis of the DENND2D-negative group showed that patients treated with neoadjuvant chemotherapy achieved longer OS than patients without neoadjuvant chemotherapy (RR = 0.179; 95% CI = 0.054-0.598; p = 0.003). DENND2D suppressed CRC proliferation in vitro and in vivo. Downregulation of DENND2D also promoted metastasis to distant organs in vivo. Mechanistically, DENND2D suppressed the MAPK pathway in CRC. Colon cancer patients who were DENND2D negative always showed a worse prognosis and were more likely to benefit from neoadjuvant chemotherapy. DENND2D may be a new prognostic factor and a predictor of the need for neoadjuvant chemotherapy in stage IV colon cancer.
Identifiants
pubmed: 35523764
doi: 10.1038/s41419-022-04885-8
pii: 10.1038/s41419-022-04885-8
pmc: PMC9076603
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Informations de copyright
© 2022. The Author(s).
Références
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
pubmed: 28248415
doi: 10.3322/caac.21395
Sobon L, Wittekind C. UICC TNM classification of malignant tumors. New York: Wiley; 2002.
Van Cutsem E, Nordlinger B, Adam R, Köhne C-H, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21.
pubmed: 16904315
doi: 10.1016/j.ejca.2006.04.012
Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis. 1984;4:170–9.
Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283.
pubmed: 23152705
pmcid: 3496330
Aloia TA, Vauthey J-N, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460–7.
pubmed: 16702517
doi: 10.1001/archsurg.141.5.460
Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197:728–36.
pubmed: 18789428
doi: 10.1016/j.amjsurg.2008.04.013
Lee W-S, Yun SH, Chun H-K, Lee WY, Kim S-J, Choi S-H, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008;42:945–9.
pubmed: 18438208
doi: 10.1097/MCG.0b013e318064e752
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.
pubmed: 18358928
pmcid: 2277487
doi: 10.1016/S0140-6736(08)60455-9
Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038–48.
pubmed: 15774795
doi: 10.1200/JCO.2005.00.349
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309.
pubmed: 10493478
pmcid: 1420876
doi: 10.1097/00000658-199909000-00004
Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807–14.
pubmed: 15143073
doi: 10.1200/JCO.2004.09.160
Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol. 2003;21:820–9.
pubmed: 12610180
doi: 10.1200/JCO.2003.05.190
Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2003;21:241–50.
pubmed: 12525515
doi: 10.1200/JCO.2003.05.044
Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137–44.
pubmed: 24104864
doi: 10.1002/cncr.28347
Amikura K, Akagi K, Ogura T, Takahashi A, Sakamoto H. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: the results from a genetic analysis of all-RAS. J Surg Oncol. 2018;117:745–55.
pubmed: 29194647
doi: 10.1002/jso.24910
Denbo JW, Yamashita S, Passot G, Egger M, Chun YS, Kopetz SE, et al. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg. 2017;21:68–77.
pubmed: 27334313
doi: 10.1007/s11605-016-3189-9
Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120:3965–71.
pubmed: 25155157
doi: 10.1002/cncr.28954
Lin Q, Ye Q, Zhu D, Wei Y, Ren L, Ye L, et al. Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases. PLoS One. 2014;9:e105747.
pubmed: 25162714
pmcid: 4146540
doi: 10.1371/journal.pone.0105747
Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, et al. Prognostic significance of proliferative activity, DNA‐ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif. 1998;31:139–53.
pubmed: 9853427
doi: 10.1111/j.1365-2184.1998.tb01192.x
Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921–8.
pubmed: 25942399
pmcid: 4580391
doi: 10.1038/bjc.2015.142
Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012;106:123–9.
pubmed: 22331825
doi: 10.1002/jso.23063
Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun D-S, Shinoura S, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci. 2013;20:223–33.
pubmed: 23010994
doi: 10.1007/s00534-012-0531-9
Jácome AA, Johnson B, editors. More than FOLFOX and FOLFIRI: the management of metastatic colorectal cancer in the era of precision oncology. EMJ Oncol. 2021;9:43–52.
Uhlig J, Cecchini M, Sheth A, Stein S, Lacy J, Kim HS. Microsatellite instability and KRAS mutation in stage IV colorectal cancer: prevalence, geographic discrepancies, and outcomes from the national cancer database. J Natl Compr Cancer Netw. 2021;19:307–18.
doi: 10.6004/jnccn.2020.7619
Bläker H, Alwers E, Arnold A, Herpel E, Tagscherer KE, Roth W, et al. The association between mutations in BRAF and colorectal cancer–specific survival depends on microsatellite status and tumor stage. Clin Gastroenterol Hepatol. 2019;17:455–62.e6.
pubmed: 29660527
doi: 10.1016/j.cgh.2018.04.015
Khan ZA, Jonas SK, Feldmann KA, Patel H, Wharton RQ, Tarragona A, et al. P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. J Cancer Res Clin Oncol. 2001;127:675–80.
pubmed: 11710597
doi: 10.1007/s004320100248
Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer. 1996;69:190–2.
pubmed: 8682586
doi: 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1:207–16.
pubmed: 28404093
doi: 10.1016/S2468-1253(16)30014-0
Hino H, Shiomi A, Kusuhara M, Kagawa H, Yamakawa Y, Hatakeyama K, et al. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. Cancer Med. 2019;8:4587–97.
pubmed: 31240875
pmcid: 6712448
doi: 10.1002/cam4.2344
Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst. 2017;109.
Yakirevich E, Resnick MB, Mangray S, Wheeler M, Jackson CL, Lombardo KA, et al. Oncogenic ALK fusion in rare and aggressive subtype of colorectal adenocarcinoma as a potential therapeutic target. Clin Cancer Res. 2016;22:3831–40.
pubmed: 26933125
doi: 10.1158/1078-0432.CCR-15-3000
Imai A, Ishida M, Fukuda M, Nashida T, Shimomura H. MADD/DENN/Rab3GEP functions as a guanine nucleotide exchange factor for Rab27 during granule exocytosis of rat parotid acinar cells. Arch Biochem Biophys. 2013;536:31–7.
pubmed: 23702376
doi: 10.1016/j.abb.2013.05.002
Marat AL, Dokainish H, McPherson PS. DENN domain proteins: regulators of Rab GTPases. J Biol Chem. 2011;286:13791–800.
pubmed: 21330364
pmcid: 3077579
doi: 10.1074/jbc.R110.217067
Marat AL, McPherson PS. The connecdenn family, Rab35 guanine nucleotide exchange factors interfacing with the clathrin machinery. J Biol Chem. 2010;285:10627–37.
pubmed: 20154091
pmcid: 2856271
doi: 10.1074/jbc.M109.050930
Yoshimura S-i, Gerondopoulos A, Linford A, Rigden DJ, Barr FA. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. J Cell Biol. 2010;191:367–81.
pubmed: 20937701
pmcid: 2958468
doi: 10.1083/jcb.201008051
Subramani D, Alahari SK. Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 2010;9:312.
pubmed: 21143914
pmcid: 3003658
doi: 10.1186/1476-4598-9-312
Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005;65:2516–9.
pubmed: 15805241
doi: 10.1158/0008-5472.CAN-05-0573
Ling B, Zheng H, Fu G, Yuan J, Shi T, Chen S, et al. Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. Lung Cancer. 2013;79:104–10.
pubmed: 23182661
doi: 10.1016/j.lungcan.2012.10.012
Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, et al. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 2014;44:44–52.
pubmed: 24189587
doi: 10.3892/ijo.2013.2165
He Y, Wu Y, Liu Z, Li B, Jiang N, Xu P, et al. Identification of signature genes associated with invasiveness and the construction of a prognostic model that predicts the overall survival of bladder cancer. Front Genet. 2021;12:694777.
pubmed: 34589112
pmcid: 8473900
doi: 10.3389/fgene.2021.694777
Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res. 2007;67:7703–12.
pubmed: 17699774
doi: 10.1158/0008-5472.CAN-07-0991
Peng J, Ou Q, Wu X, Zhang R, Zhao Q, Jiang W, et al. Expression of voltage-gated sodium channel Nav1. 5 in non-metastatic colon cancer and its associations with estrogen receptor (ER)-β expression and clinical outcomes. Chin J Cancer. 2017;36:1–10.
doi: 10.1186/s40880-017-0253-0
Peng J-H, Fang Y-J, Li C-X, Ou Q-J, Jiang W, Lu S-X, et al. A scoring system based on artificial neural network for predicting 10-year survival in stage II A colon cancer patients after radical surgery. Oncotarget. 2016;7:22939.
pubmed: 27008710
pmcid: 5008413
doi: 10.18632/oncotarget.8217
Bartha A, Gyorffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22:2622.
Zhang R-X, Zhou Z-G, Lu S-X, Lu Z-H, Wan D-S, Pan Z-Z, et al. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients. Sci Rep. 2017;7:1–10.
Hibino S, Kanda M, Oya H, Takami H, Shimizu D, Nomoto S, et al. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep. 2014;31:693–700.
pubmed: 24317529
doi: 10.3892/or.2013.2901
Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, et al. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer. 2015;18:288–96.
pubmed: 24695972
doi: 10.1007/s10120-014-0372-0
Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.
pubmed: 21383284
doi: 10.1200/JCO.2010.30.1366
Price TJ, Karapetis CS, Joanne Y, Roy A, Padbury R, Maddern G, et al. Outcomes for metastatic colorectal cancer (mCRC) based on microsatellite instability. J Clin Oncol. 2018;36:759.
Jin Z, Sanhueza CT, Johnson B, Nagorney DM, Larson DW, Mara KC, et al. Outcome of mismatch repair‐deficient metastatic colorectal cancer: The Mayo Clinic Experience. Oncologist. 2018;23:1083.
pubmed: 29674439
pmcid: 6192616
doi: 10.1634/theoncologist.2017-0289
Fujiyoshi K, Yamamoto G, Takenoya T, Takahashi A, Arai Y, Yamada M, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res. 2017;37:239–47.
pubmed: 28011498
doi: 10.21873/anticanres.11313
Charlton ME, Karlitz JJ, Schlichting JA, Chen VW, Lynch CF. Factors associated with guideline-recommended KRAS testing in colorectal cancer patients: a population-based study. Am J Clin Oncol. 2017;40:498.
pubmed: 25844824
pmcid: 4591083
doi: 10.1097/COC.0000000000000191
Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31:3664.
pubmed: 24019539
pmcid: 3789216
doi: 10.1200/JCO.2013.48.9591
Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004;35:808–16.
pubmed: 15257543
doi: 10.1016/j.humpath.2004.01.022
Holdhoff M, Schmidt K, Donehower R, Diaz LA. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst. 2009;101:1284–5.
pubmed: 19641175
doi: 10.1093/jnci/djp240
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.
pubmed: 18670422
doi: 10.1038/nm.1789
Schlüter C, Duchrow M, Wohlenberg C, Becker M, Key G, Flad H-D, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–22.
pubmed: 8227122
doi: 10.1083/jcb.123.3.513
Meyer A, Merkel S, Brückl W, Schellerer V, Schildberg C, Campean V, et al. Cdc2 as prognostic marker in stage UICC II colon carcinomas. Eur J Cancer. 2009;45:1466–73.
pubmed: 19223178
doi: 10.1016/j.ejca.2009.01.010
Shin IY, Sung NY, Lee YS, Kwon TS, Si Y, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver. 2014;8:13.
pubmed: 24516696
doi: 10.5009/gnl.2014.8.1.13
Fernández-Cebrián JM, Nevado Santos M, Vorwald Kuborn P, Pardo de Lama M, Martin-Cavanna J, Pacheco Martínez P, et al. Can the clinical outcome in state II colon carcinomas be predicted by determination of molecular marker expression? Clin Transl Oncol. 2007;9:663–70.
pubmed: 17974527
doi: 10.1007/s12094-007-0119-z
Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001;60:162–9.
pubmed: 11244332
doi: 10.1159/000055314
Salminen E, Palmu S, Vahlberg T, Roberts PJ, Söderström K-O. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005;11:3245.
pubmed: 15929175
pmcid: 4316056
doi: 10.3748/wjg.v11.i21.3245
Xi H-Q, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol. 2011;64:498–503.
pubmed: 21415057
doi: 10.1136/jcp.2010.087213
Ivanecz A, Kavalar R, Palfy M, Pivec V, Sremec M, Horvat M, et al. Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases. HPB. 2014;16:235–42.
pubmed: 23509992
doi: 10.1111/hpb.12089
Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–11.
pubmed: 24717919
doi: 10.1016/S1470-2045(14)70105-6
Nasti G, Piccirillo M, Izzo F, Ottaiano A, Albino V, Delrio P, et al. Neoadjuvant FOLFIRI+ bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566–70.
pubmed: 23558891
pmcid: 3668480
doi: 10.1038/bjc.2013.140